Arrow Left About us

Consortium strategy

The Pediatric Praziquantel Consortium aims to develop, register and provide access to a suitable pediatric treatment option for schistosomiasis in children aged 3 months to 6 years. Our strategy is comprised of two arms: (1) Building a sustainable partnership and (2) Promoting dialogue at all stakeholder levels.

The Consortium builds a sustainable partnership by:

  1. Working with credible and experienced partners
  2. Using an operating model that allows new partners to join as needed
  3. Performing a regular gap analysis to identify the need for additional expertise, resources and/or funding, and pro-actively identify future partners or funding opportunities

The Consortium pro-actively promotes dialogue at all stakeholder levels to help ensure project involvement and support through:

  1. Continuous and tailored communication of the rationale and background of the project with key stakeholders
  2. Regular consultation with experts in the field of pediatric medicine and schistosomiasis
  3. Proactive dialogue with relevant health authorities, like ANVISA (the Brazilian Health Regulatory Agency), WHO PQP (Prequalification of Medicines Program) and EMA (European Medicines Agency), to achieve registration within the shortest timeframe possible
  4. Proactive dialogue with relevant stakeholders to define a new path for equitable and sustainable access to the product, once registered

Learn more about our governance structure here.

Share this pageā€¦